Join
Live feed
·
PRReleasevia Quantisnow
Karyopharm Therapeutics Inc. logo

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

ByQuantisnow·Wall Street's wire, on your screen.
KPTI· Karyopharm Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KPTI (Karyopharm Therapeutics Inc.) and more on Quantisnow.